| scholarly article | Q13442814 |
| P50 | author | Orietta Spinelli | Q87943496 |
| P2093 | author name string | Alessandro Rambaldi | |
| Ursula Giussani | |||
| Giovanni Porta | |||
| Fulvio Porta | |||
| Luigi Caimi | |||
| Tamara Intermesoli | |||
| Eleonora Candi | |||
| Francesco Pasquali | |||
| Elia Mattarucchi | |||
| Francesco Lo Curto | |||
| Arnalda Lanfranchi | |||
| Cristina Pirrone | |||
| Chiara Boroni | |||
| Ilaria S Pagani | |||
| Diana Pigni | |||
| Elisabetta Amelotti | |||
| Federica Bolda | |||
| Renata Baffelli | |||
| Silvia Lilliu | |||
| P2860 | cites work | Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression | Q28283082 |
| Detection of DNA fusion junctions for BCR-ABL translocations by Anchored ChromPET | Q30432360 | ||
| Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. | Q31099184 | ||
| The anti-apoptotic form of tyrosine kinase Lyn that is generated by proteolysis is degraded by the N-end rule pathway | Q33757090 | ||
| Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia | Q33797115 | ||
| Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias | Q34277769 | ||
| BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia | Q34315303 | ||
| Inhibition of BCR/ABL protein expression by miR-203 sensitizes for imatinib mesylate | Q34685280 | ||
| Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. | Q35134983 | ||
| Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment | Q35553345 | ||
| Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. | Q35561038 | ||
| Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results | Q35849776 | ||
| Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era. | Q35987081 | ||
| A novel co-operative mechanism linking TGFβ and Lyn kinase activation to imatinib resistance in chronic myeloid leukaemia cells | Q36071873 | ||
| Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? | Q36328410 | ||
| Implementation of management guidelines for chronic myeloid leukemia: perspectives in the United States. | Q36401763 | ||
| Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia | Q36685759 | ||
| How I monitor residual disease in chronic myeloid leukemia | Q36846361 | ||
| The loss of the BH3-only Bcl-2 family member Bid delays T-cell leukemogenesis in Atm-/- mice | Q36920793 | ||
| All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib | Q36926106 | ||
| Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway | Q36926143 | ||
| B4GALT family mediates the multidrug resistance of human leukemia cells by regulating the hedgehog pathway and the expression of p-glycoprotein and multidrug resistance-associated protein 1 | Q36973762 | ||
| Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods | Q37022904 | ||
| European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. | Q37026032 | ||
| Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet | Q37163550 | ||
| Genetic background affects susceptibility to tumoral stem cell reprogramming. | Q37344811 | ||
| High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients | Q37381574 | ||
| Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease | Q37511071 | ||
| Monitoring disease response to tyrosine kinase inhibitor therapy in CML. | Q37653265 | ||
| Why doesn't imatinib cure chronic myeloid leukemia? | Q37685843 | ||
| Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia | Q37896015 | ||
| Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure? | Q37967263 | ||
| Standardized definitions of molecular response in chronic myeloid leukemia. | Q38002704 | ||
| Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet | Q38003129 | ||
| A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA. | Q38307018 | ||
| PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor | Q39087858 | ||
| Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells. | Q39106999 | ||
| Imatinib induces demethylation of miR-203 gene: an epigenetic mechanism of anti-tumor effect of imatinib | Q39109139 | ||
| Dual regulation of Myc by Abl. | Q39210846 | ||
| DHH-RHEBL1 fusion transcript: a novel recurrent feature in the new landscape of pediatric CBFA2T3-GLIS2-positive acute myeloid leukemia | Q39221970 | ||
| MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1.). | Q39329007 | ||
| BCR-ABL regulates death receptor expression for TNF-related apoptosis-inducing ligand (TRAIL) in Philadelphia chromosome-positive leukemia | Q39337116 | ||
| Linking miRNA regulation to BCR-ABL expression: the next dimension | Q39974225 | ||
| Dynamics of chronic myeloid leukaemia. | Q40403398 | ||
| Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity | Q41356541 | ||
| Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia | Q41673629 | ||
| Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis | Q41768874 | ||
| Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations | Q41808859 | ||
| Transcriptional regulation of immediate-early gene response by THOC5, a member of mRNA export complex, contributes to the M-CSF-induced macrophage differentiation | Q41946655 | ||
| Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming | Q41947180 | ||
| Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence. | Q42146622 | ||
| STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia | Q42153537 | ||
| In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. | Q42169875 | ||
| Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia | Q42223517 | ||
| Adding a new facet to STAT5 in CML: multitasking for leukemic cells | Q42541264 | ||
| Chronic growth factor receptor signaling and lineage inappropriate gene expression in AML: the polycomb connection. | Q42574050 | ||
| Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial | Q42851077 | ||
| Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. | Q42919964 | ||
| Organopalladium compound 7b targets mitochondrial thiols and induces caspase-dependent apoptosis in human myeloid leukemia cells | Q43105269 | ||
| New concepts for CML clonality | Q43105348 | ||
| Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia | Q43572991 | ||
| Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro | Q43833442 | ||
| Microhomologies and interspersed repeat elements at genomic breakpoints in chronic myeloid leukemia. | Q43997460 | ||
| Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia | Q44680313 | ||
| Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells | Q45133282 | ||
| Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis | Q47723259 | ||
| Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. | Q48210350 | ||
| Ponatinib circumvents all types of imatinib resistance in chronic myelogenous leukemia cell lines. | Q50994605 | ||
| Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. | Q51932390 | ||
| Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. | Q54258510 | ||
| P433 | issue | 7 | |
| P921 | main subject | leukemia | Q29496 |
| chronic myeloid leukemia | Q729735 | ||
| P304 | page(s) | 510-521 | |
| P577 | publication date | 2014-07-23 | |
| P1433 | published in | Oncoscience | Q27725796 |
| P1476 | title | Genomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid Leukemia | |
| P478 | volume | 1 |
| Q92289469 | ANXA3 Silencing Ameliorates Intracranial Aneurysm via Inhibition of the JNK Signaling Pathway |
| Q28066148 | Current developments in molecular monitoring in chronic myeloid leukemia |
| Q92383619 | Down-regulated LAMA4 inhibits oxidative stress-induced apoptosis of retinal ganglion cells through the MAPK signaling pathway in rats with glaucoma |
| Q47298176 | Effects of microRNA-330 on vulnerable atherosclerotic plaques formation and vascular endothelial cell proliferation through the WNT signaling pathway in acute coronary syndrome. |
| Q102059756 | Inactivated STAT5 pathway underlies a novel inhibitory role of EBF1 in chronic lymphocytic leukemia |
| Q37305939 | Is Adherence to Imatinib Mesylate Treatment Among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar? |
| Q91452432 | Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission |
| Q95642294 | Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances |
| Q90626263 | Overexpressed VEPH1 inhibits epithelial-mesenchymal transition, invasion, and migration of human cutaneous melanoma cells through inactivating the TGF-β signaling pathway |
| Q104487508 | Overexpression of microRNA-216a-3p Accelerates the Inflammatory Response in Cardiomyocytes in Type 2 Diabetes Mellitus by Targeting IFN-α2 |
| Q54309446 | TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation. |
| Q42910340 | gDNA Q-PCR for clinical monitoring of CML. |
| Q54123354 | gDNA qPCR is statistically more reliable than mRNA analysis in detecting leukemic cells to monitor CML. |
Search more.